Radiolabeled compounds targeting the prostate-specific membrane antigen
US-2024018110-A1 · Jan 18, 2024 · US
Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto
US8993797B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8993797-B2 |
| Application number | US-201313938548-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 10, 2013 |
| Priority date | Apr 20, 2005 |
| Publication date | Mar 31, 2015 |
| Grant date | Mar 31, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate.
First claim
Opening claim text (preview).
We claim: 1. A compound of (−) halofenate in a crystalline solid form A characterized by an X-ray powder diffraction pattern comprising a peak at about 10.8° 2θ, about 22.0° 2Θ, and 29.3° 2Θ, and an infrared spectrum comprising a peak at about 3322 cm −1 , about 3032 cm −1 , about 2958 cm −1 , about 1753 cm −1 , about 1651 cm −1 , about 1340 cm −1 and about 1017 cm −1 . 2. The compound of claim 1 , further characterized by at least one of: no weight gain at a…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
- C07C235/78Primary
Chemistry & Metallurgy · mapped topic
- C07C233/18Primary
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8993797B2 cover?
- The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also re…
- Who is the assignee on this patent?
- Cymabay Therapeutics Inc, Diatex Inc
- What technology area does this patent fall under?
- Primary CPC classification C07C235/78. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).